Breast Cancer Clinical Trial
Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery
Summary
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at the effects of surgery, radiation therapy, chemotherapy, and hormone therapy on biomarkers in women with stage I, stage II, stage III breast cancer, or ductal carcinoma in situ that can be removed by surgery.
Full Description
OBJECTIVES:
Measure the effects of surgery and radiation on concentrations of high-sensitivity C-reactive protein (hsCRP) in women with newly diagnosed stage I-III invasive breast cancer or ductal carcinoma in situ.
Measure the effects of chemotherapy and/or endocrine therapy on concentrations of hsCRP in these patients.
Summarize the differences in preoperative to peri-chemotherapy hsCRP concentrations separately for patients who do and who do not receive growth factors during chemotherapy.
Observe the change in hsCRP concentrations and gene methylation over time with local and systemic treatment in these patients.
Explore prevalence of baseline and change in methylation in a panel of genes that is known to be frequently and specifically hypermethylated in breast cancer.
OUTLINE: This is a prospective study.
A blood sample is collected at baseline, approximately 1 week after surgery, and at the time of a routine follow-up visit 3-6 months after completion of all local and systemic therapy, except for patients receiving endocrine therapy. For patients receiving adjuvant chemotherapy, a blood sample is collected prior to beginning chemotherapy and once during the final 2 courses of chemotherapy. For patients receiving radiotherapy, a blood sample is collected during the final 2 weeks of radiotherapy. For patients receiving endocrine therapy, a blood sample is collected between 2 and 6 months after starting endocrine therapy. Patients also complete a questionnaire about overall health and concurrent medications at baseline and during each follow-up visit.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically and/or cytologically confirmed stage I-III invasive breast carcinoma or ductal carcinoma in situ
Newly diagnosed disease
Patient must be initiating a new course of treatment for breast carcinoma, including surgery (mastectomy or lumpectomy with or without nodal evaluation) with or without any of the following:
Radiation therapy
Chemotherapy
Endocrine therapy
No known or suspected metastatic disease
Hormone receptor status:
Not specified
PATIENT CHARACTERISTICS:
Female
Menopausal status not specified
No infectious or inflammatory condition, at the discretion of the principal investigator
No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer
PRIOR CONCURRENT THERAPY:
More than 6 months since prior surgery
Fine-needle aspirate or biopsy allowed
More than 6 months since prior radiotherapy
More than 6 months since prior chemotherapy
More than 6 months since prior endocrine therapy
No neoadjuvant endocrine therapy or chemotherapy
More than 2 weeks since prior and no concurrent regular use of any of the following:
Hydroxymethyl glutaryl coenzyme A reductase inhibitor (statin)
Nonsteroidal anti-inflammatory drug (NSAID)*
Cyclooxygenase-2 (COX-2) inhibitor
Aspirin*
Acetaminophen and opioid use is permitted as needed NOTE: *Use of these products ≤ 2 times per week at standard over-the-counter doses allowed
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Baltimore Maryland, 21231, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.